文献速递肝病

北美HBV-HIV共感染成人组织学与临床病毒学结局的前瞻性研究

A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America.
PubMed 文献 · Hepatology · 2021-08-25

这项NIH资助的前瞻性观察研究纳入北美8个中心的139例HBV-HIV共感染成人,随访≤192周并行配对肝活检。在cART病毒学抑制背景下,临床事件发生率低(复合终点0.61/100人年),组织学活动指数仅轻微改善(3到3,P=0.02),纤维化评分无显著变化(P=0.58)。

要点

  • cART时代HBV-HIV共感染者临床事件罕见,复合终点率0.61/100人年。
  • 配对肝活检显示组织学活动指数仅轻微改善,纤维化评分无显著变化。
  • 随访期间无HBsAg清除,HBeAg清除率6.86/100人年。

核心结论

  • 在病毒学抑制的HBV-HIV共感染成人中,临床结局和组织学恶化均不常见。

研究设计与样本

  • NIH资助的前瞻性观察研究,纳入北美8个中心的139例HBV-HIV共感染成人。
  • 入组时及每24周收集数据,随访≤192周,配对肝活检在入组时和≥3年随访时获取。
  • 活检由中心病理委员会采用修改版Ishak评分系统评估。

主要发现

  • 随访数据可评估者114例,中位年龄49岁,91%为男性,51%为非西班牙裔黑人,13%有风险性饮酒,中位感染年限20年。
  • 入组时95%正在接受抗HBV cART,中位CD4计数562 cells/mm3,93% HIV < 400 copies/mL。
  • HBeAg阳性61%,HBV DNA < 20 IU/mL者61%,< 1,000 IU/mL者80%。
  • 临床事件罕见:1例肝失代偿、2例HCC、0例肝移植、1例HBV相关死亡,复合终点率0.61/100人年。
  • 新发肝硬化率0.40/100人年,ALT flare率0.65/100人年,HBeAg清除率6.86/100人年,无HBsAg清除。

临床怎么用

  • 对于cART下病毒学抑制的HBV-HIV共感染者,临床事件和组织学恶化风险较低,但组织学改善有限,仍需长期监测。

局限性

  • 配对肝活检样本量较小(n=62),可能影响组织学变化的统计效能。
  • 观察性研究,随访时间有限(≤192周),长期结局需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Histological and clinical outcomes in HBV-HIV coinfection in the era of combination antiretroviral therapy (cART) are poorly defined. APPROACH AND RESULTS: Adult patients co-infected with HBV-HIV from eight North American sites were enrolled in this National Institutes of Health (NIH)-funded prospective observational study (n = 139). Demographic, clinical, serological, and virological data were collected at entry and every 24 weeks for ≤ 192 weeks. Paired liver biopsies were obtained at study entry and at ≥ 3 years of follow-up. Biopsies were assessed by a central pathology committee using the modified Ishak scoring system. Clinical outcome rate and changes in histology are reported. Among participants with follow-up data (n = 114), median age was 49 years, 91% were male, 51% were non-Hispanic Black, and 13% had at-risk alcohol use, with a median infection of 20 years. At entry, 95% were on anti-HBV cART. Median CD4 count was 562 cells/mm3 and 93% had HIV < 400 copies/mL. HBeAg was positive in 61%, and HBV DNA was below the limit of quantification (< 20 IU/mL) in 61% and < 1,000 IU/mL in 80%. Clinical events were uncommon across follow-up: one hepatic decompensation, two HCC, no liver transplants, and one HBV-related deaths, with a composite endpoint rate of 0.61/100 person-years. Incident cirrhosis (n = 1), alanine aminotransferase flare (n = 2), and HBeAg loss (n = 13) rates were 0.40, 0.65, and 6.86 per 100 person-years, respectively. No participants had HBsAg loss. Paired biopsy (n = 62; median 3.6 years apart) revealed minimal improvement in Histologic Activity Index (median [interquartile range]: 3 [2-4] to 3 [1-3]; P = 0.02) and no significant change in fibrosis score (1 [1-2] to 1 [0-3]; P = 0.58). CONCLUSIONS: In a North American cohort of adults with HBV-HIV on cART with virological suppression, clinical outcomes and worsening histological disease were uncommon.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Sterling RK, King WC, Khalili M, et al. A Prospective Study Evaluating Changes in Histology, Clinical and Virologic Outcomes in HBV-HIV Co-infected Adults in North America. Hepatology. 2021. PMID: 33743541. doi:10.1002/hep.31823

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。